



Prescient CEO to step down in early 2025

MELBOURNE Australia, 12 September 2024: Prescient Therapeutics Limited (Prescient; ASX: PTX), a clinical stage oncology company developing personalised therapies for cancer, announces that Mr. Steven Yatomi-Clarke has advised the Board that he will step down as Managing Director and Chief Executive Officer of Prescient to pursue a new appointment. Mr. Yatomi-Clarke intends to remain in his position until the end of February 2025, and while the Company conducts a search for a new CEO.

Prescient Chair, Steve Engle, said “The Board of Directors and I deeply appreciate Steven’s outstanding leadership and strategic vision in building the Company and an international R&D team over the last eight years and gaining the support of some of the most renowned thought leaders in cancer therapies. He has led the development of our PTX-100 oncology candidate, which began as a research stage project, and has produced positive clinical results, such that the project is now on the cusp of initiating a Phase 2 study. In addition, Steven has positioned Prescient very favourably in the nascent cell therapy field with two enabling platform technologies, by devising CellPryme and leading its development, and identifying the potential of an innovative modular approach in cell therapy, creating OmniCAR with licenses from technology pioneers Penn and Oxford. His worldwide business development efforts have established Prescient as a recognized leader in novel cancer therapies, and the Company has initiated discussions with dozens of potential pharmaceutical corporate partners. We will miss Steven and wish him the very best in his new venture.”

Mr Yatomi-Clarke said, “It has been a privilege to serve as CEO of Prescient and I am so proud of what Prescient has achieved during my tenure. I remain very excited about the Company’s prospects - Prescient is well placed and on a very exciting trajectory with all its programs. I am also very honoured to have led such a talented group of people who are committed to developing new therapies for patients, and with the grit and determination that this challenge requires. I am committed to ensuring that we do not lose operational momentum in the coming months, with a number of important milestones, including the commencement of our Phase 2 trial of PTX-100 in T cell lymphomas”.

The Board of Prescient will conduct a search for a new CEO to continue the Company’s momentum. If required, Mr Engle, will act as Executive Chair until the appointment of the new



CEO. Following the appointment of his successor, Mr Yatomi-Clarke has agreed to remain available as a consultant to Prescient to provide ongoing assistance to the Company.

Mr. Yatomi-Clarke has been selected as the inaugural CEO of Aurora Biosynthetics, a private company that will spearhead the development of an RNA ecosystem in Australia, backed by over \$200 million of NSW government support.

Prescient will hold a brief webinar with Chair, Mr Steve Engle, and Managing Director and CEO, Mr Steven Yatomi-Clarke **this morning at 9 am Australian Eastern Standard Time**. The webinar can be accessed on the following link:

<https://prescienttherapeutics.investorportal.com.au/investor-briefing/>

– Ends –

To stay updated with the latest company news and announcements, [please update your details](#) on our investor centre.

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Targeted Therapy

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it is showing encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas. A Phase 2 study is in planning.

Cell Therapy Platforms

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.



OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter [@PTX_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/ptxtherapeutics).

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

Steve Engle
Chair
Prescient Therapeutics
sengle@ptxtherapeutics.com

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics
steven@ptxtherapeutics.com

Investor enquiries

Christian Riedel
Reach Markets
1300 805 795
ir@reachmarkets.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-



looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website: [Supplemental COVID-19 Risk Factors](#)